Conditions: Multiple Sclerosis
Keywords: Multiple sclerosis safety open label Polyphenon E EGCG NAA N-acetyl-aspartate MRI
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
This study is an open label 6 month study. All subjects will be treated with Polyphenon E (400 mg EGCG twice a day) for six months. The main outcome of this pilot phase will be safety. Secondary outcomes are the change in NAA levels over 6 months as measured by MR-spectroscopy. NAA levels are a marker of neuronal function. We think that Polyphenon E will protect neurons and thus increase NAA levels.

Detailed description:
Additional clinical data include changes in EDSS, MS functional composite and cognitive testing.

Arms:
arm 1: Standarized green tea extract containing 50% EGCG

Interventions: intervention 1: Polyphenon E
Intervention descriptions: intervention 1: Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.

Protocol document: